• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

无症状非酒精性脂肪性肝病——一项临床组织学研究

Silent non-alcoholic fatty liver disease-a clinical-histological study.

作者信息

Sorrentino Paolo, Tarantino Giovanni, Conca Paolo, Perrella Alessandro, Terracciano Maria Luigi, Vecchione Raffaella, Gargiulo Giovanna, Gennarelli Nicola, Lobello Roberto

机构信息

Section of Hepatology in Internal Medicine, Department of Clinical and Experimental Medicine, Federico II University Medical School, Via S. Pansini 5, 80131 Naples, Italy.

出版信息

J Hepatol. 2004 Nov;41(5):751-7. doi: 10.1016/j.jhep.2004.07.010.

DOI:10.1016/j.jhep.2004.07.010
PMID:15519647
Abstract

BACKGROUND/AIMS: We studied the prevalence of non-alcoholic fatty liver disease and non-alcoholic-steatohepatitis in patients with metabolic-syndrome but normal liver enzymes. The histological findings of patients with normal liver enzymes and non-alcoholic-steatohepatitis were compared with those of a control-group with persistently abnormal liver enzymes.

METHODS

Patients presenting with normal liver enzymes were enrolled in the study and underwent liver biopsy. Prevalence of non-alcoholic-steatohepatitis and risk factors for fibrosis and cirrhosis were evaluated. Data from a control-group with non-alcoholic-steatohepatitis and abnormal liver enzymes were used to compare the histological findings.

RESULTS

Fifty-eight of the 80 patients enrolled had varying degrees of non-alcoholic steatohepatitis, of these 26 had fibrosis and 8 silent cirrhosis. The association of metabolic-syndrome, female-sex, a long-history of obesity and body mass index>45 were considered to be independent risk-factors for fibrosis. Comparing the histological findings of cases and controls we found a similar severity of steatosis and fibrosis, with a greater prevalence of ballooning degeneration and glycogenated-nuclei rather than lobular-inflammation.

CONCLUSIONS

In the subjects selected according to our criteria, liver enzyme levels could not be used as surrogate markers of non-alcoholic-steatohepatitis. Histological hallmarks of patients with metabolic-syndrome, normal liver enzymes and non-alcoholic-steatohepatitis consist to a lesser degree of lobular-inflammation and a more severe ballooning and glycogenated-nuclei.

摘要

背景/目的:我们研究了代谢综合征患者中肝酶正常情况下非酒精性脂肪性肝病和非酒精性脂肪性肝炎的患病率。将肝酶正常且患有非酒精性脂肪性肝炎患者的组织学结果与肝酶持续异常的对照组进行比较。

方法

纳入肝酶正常的患者进行研究并接受肝活检。评估非酒精性脂肪性肝炎的患病率以及纤维化和肝硬化的危险因素。使用来自非酒精性脂肪性肝炎且肝酶异常的对照组数据比较组织学结果。

结果

纳入研究的80例患者中,58例有不同程度的非酒精性脂肪性肝炎,其中26例有纤维化,8例有静止性肝硬化。代谢综合征、女性、肥胖病史长和体重指数>45被认为是纤维化的独立危险因素。比较病例组和对照组的组织学结果,我们发现脂肪变性和纤维化的严重程度相似,气球样变性和糖原核的患病率更高,而非小叶性炎症。

结论

在根据我们的标准选择的受试者中,肝酶水平不能用作非酒精性脂肪性肝炎的替代标志物。代谢综合征、肝酶正常且患有非酒精性脂肪性肝炎患者的组织学特征是小叶性炎症程度较轻,气球样变性和糖原核更严重。

相似文献

1
Silent non-alcoholic fatty liver disease-a clinical-histological study.无症状非酒精性脂肪性肝病——一项临床组织学研究
J Hepatol. 2004 Nov;41(5):751-7. doi: 10.1016/j.jhep.2004.07.010.
2
Hepatic histopathology of morbid obesity: concurrence of other forms of chronic liver disease.病态肥胖的肝脏组织病理学:其他形式慢性肝病的并发情况。
Obes Surg. 2006 Dec;16(12):1584-93. doi: 10.1381/096089206779319392.
3
Metabolic syndrome is associated with severe fibrosis in chronic viral hepatitis and non-alcoholic steatohepatitis.代谢综合征与慢性病毒性肝炎和非酒精性脂肪性肝炎中的严重肝纤维化相关。
Aliment Pharmacol Ther. 2008 Jan 1;27(1):80-9. doi: 10.1111/j.1365-2036.2007.03538.x. Epub 2007 Oct 5.
4
Metabolic and histological features of non-alcoholic fatty liver disease patients with different serum alanine aminotransferase levels.不同血清丙氨酸氨基转移酶水平的非酒精性脂肪性肝病患者的代谢和组织学特征。
Aliment Pharmacol Ther. 2009 Feb 15;29(4):387-96. doi: 10.1111/j.1365-2036.2008.03896.x. Epub 2008 Nov 17.
5
Non-alcoholic steatohepatitis in children.儿童非酒精性脂肪性肝炎
Pediatr Transplant. 2004 Dec;8(6):613-8. doi: 10.1111/j.1399-3046.2004.00241.x.
6
[Clinical and histological features of non-alcoholic fatty liver disease].非酒精性脂肪性肝病的临床和组织学特征
Zhonghua Gan Zang Bing Za Zhi. 2009 Nov;17(11):812-6.
7
Prevalence of undiagnosed diabetes and postchallenge hyperglycaemia in Chinese patients with non-alcoholic fatty liver disease.中国非酒精性脂肪性肝病患者中未诊断糖尿病和糖负荷后高血糖的患病率
Aliment Pharmacol Ther. 2006 Oct 15;24(8):1215-22. doi: 10.1111/j.1365-2036.2006.03112.x.
8
Nonalcoholic fatty liver disease in severely obese subjects.严重肥胖受试者的非酒精性脂肪性肝病
Am J Gastroenterol. 2007 Feb;102(2):399-408. doi: 10.1111/j.1572-0241.2006.01041.x.
9
Non-alcoholic steatohepatitis in type 2 diabetes mellitus.2型糖尿病中的非酒精性脂肪性肝炎
J Gastroenterol Hepatol. 2004 Aug;19(8):854-8. doi: 10.1111/j.1440-1746.2004.03312.x.
10
Hepatic histology in obese patients undergoing bariatric surgery.接受减肥手术的肥胖患者的肝脏组织学。
J Hepatol. 2006 Oct;45(4):600-6. doi: 10.1016/j.jhep.2006.06.013. Epub 2006 Jul 25.

引用本文的文献

1
Liver Disease and Prevalence of Liver Transplantation in Adults With ZZ Alpha-1 Antitrypsin Deficiency-A Meta-Analysis.ZZα-1抗胰蛋白酶缺乏症成人患者的肝脏疾病与肝移植患病率——一项荟萃分析
Liver Int Commun. 2025 Jun;6(2):e70013. doi: 10.1002/lci2.70013. Epub 2025 Apr 11.
2
Prevalence and Associated Factors of Non-Alcoholic Fatty Liver Disease in People Living with HIV-1.HIV-1感染者中非酒精性脂肪性肝病的患病率及相关因素
Curr HIV Res. 2025;23(2):121-132. doi: 10.2174/011570162X340918250312040500.
3
Triglyceride-glucose-alanine aminotransferase index: A noninvasive serum predictor for identifying the severity of pediatric nonalcoholic fatty liver disease.
甘油三酯-葡萄糖-丙氨酸转氨酶指数:一种用于识别小儿非酒精性脂肪性肝病严重程度的非侵入性血清预测指标。
Medicine (Baltimore). 2024 Jun 28;103(26):e38241. doi: 10.1097/MD.0000000000038241.
4
[Not Available].[无可用内容]
Adv Lab Med. 2024 Feb 14;5(2):131-147. doi: 10.1515/almed-2023-0172. eCollection 2024 Jun.
5
Serum biomarkers for liver fibrosis assessment.用于肝纤维化评估的血清生物标志物。
Adv Lab Med. 2023 Nov 14;5(2):115-130. doi: 10.1515/almed-2023-0081. eCollection 2024 Jun.
6
NASHmap: clinical utility of a machine learning model to identify patients at risk of NASH in real-world settings.NASHmap:一种机器学习模型在真实环境中识别 NASH 风险患者的临床应用。
Sci Rep. 2023 Apr 5;13(1):5573. doi: 10.1038/s41598-023-32551-2.
7
Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments.非酒精性脂肪性肝病中肝脂肪变性的非侵入性血清生物标志物:现状与未来发展。
Clin Mol Hepatol. 2023 Feb;29(Suppl):S150-S156. doi: 10.3350/cmh.2022.0362. Epub 2023 Jan 25.
8
The association between non-alcoholic fatty liver disease (NAFLD) and advanced fibrosis with blood selenium level based on the NHANES 2017-2018.基于 NHANES 2017-2018 的血硒水平与非酒精性脂肪性肝病(NAFLD)和肝纤维化程度的关系。
Ann Med. 2022 Dec;54(1):2259-2268. doi: 10.1080/07853890.2022.2110277.
9
HOMA-IR index in non-diabetic patient, a reliable method for early diagnosis of liver steatosis.非糖尿病患者的HOMA-IR指数,一种早期诊断肝脂肪变性的可靠方法。
Caspian J Intern Med. 2022 Summer;13(3):519-526. doi: 10.22088/cjim.13.3.519.
10
SGLT2 Inhibitors as the Most Promising Influencers on the Outcome of Non-Alcoholic Fatty Liver Disease.钠-葡萄糖协同转运蛋白 2 抑制剂作为影响非酒精性脂肪性肝病结局最有前途的影响因子。
Int J Mol Sci. 2022 Mar 27;23(7):3668. doi: 10.3390/ijms23073668.